

## Vidutolimod sodium

|                          |  |
|--------------------------|--|
| <b>Cat. No.:</b>         | HY-148511A   |
| <b>Molecular Weight:</b> | 10301.9  |
| <b>Target:</b>           | Toll-like Receptor (TLR)   |
| <b>Pathway:</b>          | Immunology/Inflammation  |
| <b>Storage:</b>          | -20°C, sealed storage, away from moisture<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |

## Vidutolimod (sodium)

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 100 mg/mL (9.71 mM)  
\* "≥" means soluble, but saturation unknown.

| Solvent                   | Mass  | Concentration |           |           |
|---------------------------|-------|---------------|-----------|-----------|
|                           |       | 1 mg          | 5 mg      | 10 mg     |
| Preparing Stock Solutions | 1 mM  | 0.0971 mL     | 0.4853 mL | 0.9707 mL |
|                           | 5 mM  | 0.0194 mL     | 0.0971 mL | 0.1941 mL |
|                           | 10 mM | ---           | ---       | ---       |

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFN $\alpha$ ) release, leading to a cascade of anti-tumor immune effects.

### REFERENCES

- [1]. Ribas A, Medina T, Kirkwood JM, et al. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. *Cancer Discov.* 2021;11(12):2998-3007.
- [2]. Sabree SA, Voigt AP, Blackwell SE, et al. Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. *J Immunother Cancer.* 2021;9(6):e002484.
- [3]. Cheng Y, Lemke-Miltner CD, Wongpattaraworakul W, et al. In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. *J Immunother Cancer.* 2020;8(2):e000940.

---

[4]. Negro MV, Papadimitrakopoulou VA, Price AC, et al. Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. JTO Clin Res Rep. 2022;4(3):100423. Published 2022 Oct 26.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA